Skin infection sheds light on immune cells living in our skin
BOSTON, MA—Very recently, researchers discovered an important population of immune cells called memory T cells living in parts of the body that are in contact with the environment (e.g., skin, lung, GI tract). How these "resident" memory T cells are generated was unknown, and their importance with regard to how our immune system remembers infection and how it prevents against re-infection is being studied intensively.
Now, a study by a Brigham and Women's Hospital (BWH) research team led by Xiaodong Jiang, PhD, research scientist and Thomas S. Kupper, MD, Chair of the BWH Department of Dermatology, and the Thomas B. Fitzpatrick Professor of Dermatology at Harvard, has used a model involving a vaccinia virus infection of the skin to answer important questions about how these newly discovered cells protect us.
The study will be electronically published on February 29, 2012 in Nature.
Jiang and Kupper used skin infection with vaccinia virus to study the relative roles of central memory T cells (T cells that circulate in the bloodstream) and resident memory T cells in protective immunity. What they found was that after infection, disease-specific T cells were rapidly recruited not only to the infected site, but also to all areas of skin.
They further showed that multiple additional infections at future time points led to an accumulation of even more of these resident memory T cells in the skin, and that these cells remained in the skin for long periods of time.
Finally, Jiang and Kupper showed, for the first time, that resident memory T cells were the most important protective immune cells in fighting infection—much more important than central memory T cells, which were ineffective at rapid immune protection by themselves.
"Finding that resident memory T cells were so much more important than central memory T cells in protective immunity was surprising, and makes us re-think current immunologic dogma," said Kupper.
While skin was used as a model system in this study, the results can be extrapolated to the lungs, GI tract, and other epithelial tissues that contact the outside world.
The findings suggest that the most important elements of T cell memory to infectious diseases may reside in tissues, rather than in the blood.
"The immune system provides the right T cells, at the right place and time, to protect us from an environment that is full of potentially harmful pathogens." said Kupper.
Also, the findings imply that vaccines should be optimized to create precisely this kind of long lasting tissue-resident T cell immunity, and that the current focus on antibody production may not be as important.
"This work suggests a fundamental reassessment of how vaccines are both constructed and delivered," said Kupper. "These results have altered the way we think about the immune system and vaccination for infectious diseases."
Article source: http://www.sciencecodex.com/skin_infection_sheds_light_on_immune_cells_living_in_our_skin-86973
Skin-Deep Immunity
The smallpox vaccine was the first, and arguably most successful, vaccine ever put into practice, and it was scratched into the skin of individuals. With the invention of syringes and hypodermic needles, vaccination shifted toward administration directly into the muscle, under the assumption that it is better to get a vaccine straight into the body. But it turns out scientists may have had it right the first time.
A paper published this week in Nature suggests that the most important part of the human immune system actually resides in peripheral tissues, and that vaccination through those tissues may be more effective than traditional vaccination into the muscle.
The finding is “quite remarkable,” said Onur Boyman, an immunologist at the University of Zurich, who was not involved in the current study. The researchers showed that a population of immune cells called resident memory T cells, which are present in parts of the body that are in contact with the environment, such as the skin, gut, and lungs, mediate an immune response far stronger than circulating, or central, memory T cells in the blood stream.
“In the past, people have conducted in vivo experiments that suggest resident memory and circulating memory cells confer comparable protection,” said Boyman, who identified some of the first resident memory T cells in the skin in 2004. “This paper provides a nice step forward in showing that these resident memory cells are indeed more effective against a skin infection as compared to central memory cells.”
In 2006, Rachael Clark and Thomas Kupper of Brigham and Women’s Hospital in Boston demonstrated that there is a large pool of resident memory T cells in normal skin that initiates and maintains immune reactions in the absence of T cells from the blood. Last year they showed that similar T cells exist in the lungs. The presence of these cells in our peripheral organs makes sense, said Kupper, because these tissues are the first line of defense against infection. The cells are “ready to fight invaders as soon as the barriers are breached,” he said.
A human T cell spanNIAID/NIH/span
In the current study, Kupper, Clark, and their team pitted resident memory T cells against circulating memory T cells in a heads-up match to determine which type of immune cell provides stronger protection against viral re-infection. The researchers infected mice with vaccinia virus, the core component of the smallpox vaccine, to create three different groups: mice with both circulating memory cells and skin resident memory cells, and mice with either one or the other. Each type of mouse was then challenged again with the virus.
“The resident memory cells won hands down,” said Kupper. “It wasn’t even a contest. They’re much more effective.” The mice with active resident memory T cells cleared the infection in 6 days, whether or not circulating memory T cells were present. The mice with only circulating memory T cells took 20 days to clear the infection, only slightly better than the 25 days it took mice that had never been exposed to the virus.
The team also showed that resident memory T cells reside not only at the site of infection, but spread throughout the entire skin and remain present for at least 6 months. Repeated infections in the skin resulted in higher concentrations of resident memory T cells each time.
“We’re injured and infected through the skin many times during our lives, and we think this leads to the accumulation of populations of T cells that [spread] throughout our skin and stay there for long periods of time,” said Kupper.
If the finding holds up, it means that vaccine trials are targeting the wrong cells in the body, said Kupper. Vaccination through peripheral organs, like the skin, lungs, or GI tract, could be more effective than injecting a vaccine into muscle. “It’s a wake up call that we need to think about these T cells when we’re making vaccines, he said.
The results could also mean that researchers are looking at the wrong cell population when measuring the vaccine’s effectiveness. Traditional vaccine trials measure either antibodies in the bloodstream, produced by B cells, or circulating memory T cells. “We’re missing the population of cells we’re trying to make when we vaccinate,” said Kupper, who last year co-founded a vaccine biotech exploring the delivery of vaccine through the upper layers of the skin.
Using the finding to attempt new routes of vaccination “might be plausible,” said Boyman, but first it will be important to find out how the T cells are retained in the skin and how long they stick around. “Would one need to boost the vaccines, and if so, how frequently?” he asked.
The study also has implications for understanding organ-specific immune diseases like psoriasis, asthma, and multiple sclerosis, which may involve renegade resident memory T cells, said Kupper. “The scientific implications are broad.”
X. Jiang et al., “Skin infection generates non-migratory memory CD81 TRM cells providing global skin immunity,” Nature, doi:10.1038/nature10851, 2012.
Article source: http://the-scientist.com/2012/02/29/skin-deep-immunity/
NuWelle™ Skin Care Debuts in Los Angeles Amid the Glamor of Oscar Gala
LOS ANGELES: the beauty secret of Russia's A-list is out all over LA.
Los Angeles, CA (PRWEB) February 29, 2012
NuWélle™ made its US debut on Sunday February 26th at the Children Uniting Nations Charity Gala Oscar viewing party in Beverly Hills, hosted by Pierce Brosnan, Jane Seymour, Wyclf Jean and Radha Mitchell. Actresses like Sharon Stone, Rosanna Arquette, Nia Peeples, Nia Long, Beverly Todd, and Bai Ling were treated to the products and especially were clamoring for the Transforming Serum, which promotes a lifted, firmer, younger looking complexion and protects against environmental damage.
NuWélle™ is a premium skin care line designed with the latest scientific advances and cutting edge technologies. NuWélle™ is a melding of the art of science and beauty consisting of four principle products which, when used in conjunction with one another, bring forth a youthful, healthy, and balanced face.
The skin care line is the newest extension of the company's highly advanced WellnessPro® Balanced Nutrition line of meal replacement products which were exclusively developed under the supervision of an international nutrition expert and former United States Presidential and Olympic Team advisor. All the A-list and VIP guests of the event were also given gender-specific formulas of the WellnessPro® meal replacement powders in addition to the skin care products.
"Everything in our collection been developed to embrace the principle that beauty comes from the inside, out and 80% of the way your skin looks comes from the things you eat and drink," says Tatiana Kolpakov, M.D, Vice President of Marketing for WellnessPro®. "Our nutrition supplements support maximum whole body health with easily-absorbed broad spectrum vitamins, proteins and minerals."
NuWélle™ Skin Care line launched exclusively in Moscow on December 10th, 2011 as a brand extension of WellnessPro International, a high end nutritional company that was established in 2005 and is based out of Woodland Hills, California.
WellnessPro® products are created by world experts utilizing the latest discoveries in biochemistry and dietology to deliver the best and most advanced nutritional and personal care solutions offered by the industry today. WellnessPro® products are 100% natural, ecologically clean, have no genetic modification, use advanced cold processing and chelate technology, gluten free, no wheat, no yeast, Aspartame free, with no artificial colors.
###
For the original version on PRWeb visit: www.prweb.com/releases/prweb2012/2/prweb9236923.htm
Article source: http://www.sfgate.com/cgi-bin/article.cgi?f=/g/a/2012/02/29/prweb9236923.DTL
Skin, Cosmetic Clinic at Starcare Hospital
MUSCAT — Starcare Hospital has brought a fully qualified dermatologist to provide expert medical help on a range of skin-related problems. Dr Sushma, who has several years of experience, emphasises the need to treat skin problems medically instead of resorting to quick over-the-counter remedies.
A new generation 50-bed hospital with state-of-the-art equipment, Starcare Hospital offers a wide range of services for patients in Muscat. The Department of Dermatology provides advanced cosmetic treatment to help improve and maintain the appearance of skin in both men and women.
Acne, the skin problem that never seems to go away, now has several satisfying treatments that can help restore your skin to a glowing state of health and vitality. Dr Sushma uses tools like chemical peels and dermabrasion.
She explains: “The process of dermabrasion involves removing the top layer of skin with an electric machine that abrades the skin. As the skin heals from the procedure, the surface appears smoother and fresher.”
Another popular treatment for sun-damaged skin or irregular pigmentation is chemical peels. The top layer of skin is removed with a chemical application following which, the skin regenerates, giving a fresh and radiant complexion, adds Dr Sushma.
Starcare Hospital, located at Seeb, also treats more complex skin disorders including psoriasis, atopic dermatitis and diseases of other organ systems with skin manifestations.
Dr Sushma, a dermatologist, cosmetic physician and dermatolaser surgeon, is fully qualified to perform major and minor dermatosurgical procedures, including the non-cultured melanocyte transplants and carbon dioxide lasers.
Dr Sushma emphasises the necessity of detailed scrutiny of patients being examined for simple rashes, pigmentation etc, as these could be signs of more serious disorders. The diagnosis of an autoimmune disease is based on an individual’s symptoms, findings from a physical examination and results from laboratory tests.
Autoimmune disease can be difficult to diagnose, particularly early in the course of the disease. Symptoms of many autoimmune diseases — such as fatigue — are nonspecific.
In some cases, a specific diagnosis can be made. A diagnosis shortly after onset of a patient’s symptoms will allow for early aggressive medical therapy; and for some diseases, patients will respond completely to treatments if the reason for their symptoms is discovered early in the course of the disease.
“Patients should be monitored closely so environmental factors or triggers that may worsen the disease can be discussed and avoided and new medical therapy can be started as soon as possible. Frequent visits to the doctor are important to manage complex treatment regimens and watch for medication side effects,” states Dr Sushma.
Dr Sushma is an expert skin care specialist with a special interest in general medical, paediatric dermatology; surgical and cosmetic surgery. She is a member of many dermatological associations and attends several international conferences on the subject.
Article source: http://main.omanobserver.om/node/85258
Harvard-Born TremRx Pursues New Vaccine Technology
Arlene Weintraub2/29/12Leave a CommentFollow @awjourn
Boston-based TremRx is coming out of stealth mode today with a study that describes the startup’s method of using immune cells in the skin to mobilize the body’s disease-fighting defenses. The company, founded by Harvard dermatology professor Thomas Kupper, has identified several opportunities to develop vaccines for a range of illnesses, from cancer to viruses such as hepatitis C.
TremRx was founded on discoveries by Kupper, who studies immune cells called T Resident Effector Memory cells (TREMs). In the study, published in the online edition of the journal Nature, Kupper and his team of researchers showed that these cells, which are prevalent in the skin, produced strong and durable immunity to smallpox when a version of the vaccine was delivered to the skin of animals. TremRx has developed a technology platform that’s designed to activate TREMs in the upper layers of the skin.
TremRx president Eric Stromquist, a former hedge fund manager, says the company’s goal is to change the paradigm in vaccine development. Traditional vaccines are designed to stimulate the B cell arm of the immune system to create antibodies against diseases. These vaccines, which are typically weakened versions of viruses, work in part by prompting the body to convert some immune cells into circulating “memory” T cells, which will recognize the infection in the future and help eliminate it from the body. “The whole notion of TREMs breaks with immunological dogma,” Stromquist says. “What we’ve shown is that they are in fact more protective against infection than circulating T cells.”
Stromquist says the company is pursuing a two-pronged strategy for commercializing its technology. TremRx will partner with pharmaceutical companies that want to use the startup’s technology to develop new vaccines or more effective versions of currently marketed vaccines. TremRx will also build its own pipeline of vaccines. The company has not yet revealed which diseases it’s working on, but Stromquist says the technology could be broadly applicable. Several viruses lend themselves to a TREM approach, including herpes, hepatitis, and HPV, Stromquist says. The company’s approach may also work in certain cancers. For example, Stromquist says, a TREM-based vaccine might be able to prevent melanoma from returning after the main tumor is removed surgically.
The company’s scientific advisory team includes MIT professor and (and Xconomist) Robert Langer, a prolific entrepreneur who has founded more than 17 Boston-area companies.
TremRx has been funded by angels and is currently working on raising a Series A round, Stromquist says. He says the company’s discussions with venture capitalists have been encouraging and he expects to be able to close a funding round within a year. “We feel we have a good strategy,” he says. “This whole venture is based on a significant enhancement of the understanding of how the immune system functions.”
Arlene Weintraub is the editor of Xconomy New York. She can be reached at aweintraub@xconomy.com and followed on Twitter @awjourn.
Article source: http://www.xconomy.com/boston/2012/02/29/harvard-born-tremrx-pursues-new-vaccine-technology/
Boca chamber honors doctor, young business owner – Sun
A Colombian-born dermatologist, college professor and research scientist rolled into one, and a young entrepreneur at Eagles Landing Middle School were honored at this year's Diamond Award Luncheon, the highest honor the Greater Boca Raton Chamber of Commerce gives to women in business who give back to the community.
Chamber president and CEO Troy McLellan called Boca Raton dermatologist Dr. Marta I. Rendon an "inspiration." And last year's honoree, publisher Margaret Mary Shuff described her as "passionate and driven" at the awards presentation attended by 298 people Feb. 23 at the Boca Raton Marriott.
Rendon is well known in Boca Raton through her practice, The Rendon Center for Dermatology and Aesthetic Medicine, and her charitable efforts for the Spirit of Giving Network, Soroptimist, the Junior League and Boca Raton Regional Hospital and Florence Fuller Child Development Centers.
Dermatology
Medical Specialization
Hospitals and Clinics
-
See more topics »
"Nothing is more important to me than helping other women achieve their potential. You must have a clear idea of what you want, pursue it and never give up," said Rendon. She thanked her parents for their support through medical school, when "Hispanic women doctors were a rarity."
Seventh-grader Rebecca Zerbo received $1,000 from Mary Wong, president of the Office Depot Foundation, for Positive Pocket. Rebecca started the business with an anti-bullying message as part of Young Entrepreneurs Academy, a national program for sixth- to 12th-graders the chamber has started to offer here.
The Diamond Award is an acronym for dedicated, inspiring, accomplished, motivated, outstanding, noble and driven, noted Cheryl Budd, the chamber's board chairwoman and the 2010 Diamond recipient.
Placing a pair of high heels on the dais, she alluded to the dance sequences in "Iron Lady" the movie about Margaret Thatcher. "They're a metaphor for how all working women go through life trying to choreograph their family and job," said Budd, chief communications officer for NCCI Holdings Inc., the luncheon's major sponsor.
Budd noted that more women are running Fortune 500 companies, but they still only number 18. "Networking with a capital N is building genuine relationships to help foster and mentor each other. We all have to do more," she said.
Hospital foundation president Jan Savarick delivered the invocation at the luncheon. West Boca's "American Idol" finalist Brett Loewenstern sang the National Anthem. "That was awesome," McLellan told him.
Article source: http://www.sun-sentinel.com/news/palm-beach/boca-raton/fl-brf-diamond-0229-20120229,0,7705430.story
Nu Skin Enterprises (NUS) Rose Past Resistance At The Highs
Join the NASDAQ Community today and get free, instant access to portfolios, stock ratings, real-time alerts, and more!
Article source: http://www.nasdaq.com/article/nu-skin-enterprises-nus-rose-past-resistance-at-the-highs-20120229-00361
Manuka Honey: Topical aid for skin enhancement and healing
Recently while traveling in New Zealand, I had the opportunity to learn more about a remedy that derives from a plant native to that country. Manuka honey, made from the collected nectar of the plant Leptospermum scoparium, is a widely employed, well studied topical aid for a variety of wounds, burns, cuts, infections and other skin problems.
Honey has been used for many years in beauty, medicine, and embalming, due to its aseptic composition. Bacteria cannot grow in honey, and thus it is excellent where bacteria may otherwise flourish. But manuka honey goes far beyond other honeys, actually sending out specific agents that fight bacteria and inflammation.
To make this special honey, beekeepers set their hives in areas rich in the native manuka plant. The bees gather nectar and pollen from the large green manuka bushes, and this adds up to a medical honey.
In New Zealand, and now in other parts of the world, “medical manuka honey,” is used on intractable burns and other wounds that do not respond well to other therapies. In the U.S. and the U.K., the medical supplier MediHoney provides manuka honey-impregnated bandages, as well as manuka honey creams, lotions and gels, for use in medical offices and hospitals.
I spoke with Dr Ralf Schlothauer at Comvita, New Zealand’s largest supplier of medical manuka honey, about what makes this honey so unique. According to Dr. Schlothauer, true medical manuka is sold with a “UMF” label, a seal that the honey contains what is known as “unique manuka factor.” Schlothauer said that unique factor is a concentration of antioxidant phenols that inhibit bacterial growth. Medical manuka honeys vary in UMF concentration, from as low as 5% to as high as 20% UMF.
Additionally, according to papers published in both the journal Food Chemistry and the journal Immunopharmacology and Immunotoxicology, manuka honey contains novel proteins known as arabinogalactans, which appear to enhance immune activity at wound sites where manuka honey is applied. Further studies have shown that application of medical manuka honey to wounds causes the release of anti-inflammatory cytokines.
Dr Schlothauer, and other researchers with whom I spoke, described the ability of medical manuka honey to arrest grave cases of infection. In several documented instances, patients headed for limb amputation were able to be spared the surgery after treating infected wounds with medical manuka honey. Diabetic ulcers, venous leg ulcers and infections due to serious injury have all responded well to the honey’s treatment.
Burns, which often take a long time to heal, respond more quickly to medical manuka honey treatment than to treatment with other topical applications, resulting in the formation of new, healthy skin tissue. For this reason, medical manuka honey is a regular part of burn care in New Zealand hospitals.
Medical manuka honey is a good example of how a natural remedy can travel from traditional cultural use along the road of high science to modern medical application. Manuka honey is a remedy originally used by New Zealand’s native Maori as part of their indigenous medicine. From that beginning, scientists have analyzed the honey to identify its unique properties, and have determined how medical manuka honey acts as an anti-infective, and how it fights inflammation.
Medical manuka honey is not so well known in the US at present. But with a growing body of science and an excellent track record of use for tough skin problems, this therapeutic aide will undoubtedly become more popular over time. In addition, medical manuka honey is showing up in some cosmetic lotions and creams as a beauty aide. For medical manuka honey, the future appears bright.
Chris Kilham is a medicine hunter who researches natural remedies all over the world, from the Amazon to Siberia. He teaches ethnobotany at the University of Massachusetts Amherst, where he is Explorer In Residence. Chris advises herbal, cosmetic and pharmaceutical companies and is a regular guest on radio and TV programs worldwide. Chris is the author of 14 books, including Hot Plants, Tales from the Medicine Trail, Kava: Medicine Hunting in Paradise, The Whole Food Bible, Psyche Delicacies, and the international best-selling yoga book, The Five Tibetans. Richard Branson features Chris in his new book, Screw Business as Usual. His field research is largely sponsored by Naturex of Avignon, France. Read more at www.MedicineHunter.com.
Article source: http://www.foxnews.com/health/2012/02/28/manuka-honey-topical-aid-for-skin-enhancement-and-healing/?&test=digh
Clogged Pores? Unclog with DDF and Clarisonic
Beauty Research, a beauty blogging web site, recommends solutions for clogged pores by DDF and Clarisonic.
Newport Beach, CA (PRWEB) February 28, 2012
Beauty Research, a beauty blogging web site, recently proposed solutions for clogged pores by DDF and Clarisonic. DDF is a skin care brand that offers a wide variety of solutions for a number of skin types and concerns, including clogged pores and blemish prone skin. Clarisonic became widely known in the beauty business for its electronic cleansing brush. Recently the brand introduced its Clarisonic Mia 2 as well as a deep cleansing brush head specifically developed for clogged pores.
"There are certain skin conditions that are particularly frustrating and are sometimes very difficult to treat. And those who struggle with clogged pores and congested skin are certainly among this group of people with frustrating skin indications. Those of you who suffer with congested and inflamed skin and large blocked pores AND are going through a great deal of stress over it... we want you to know that there is indeed help and are very effective products to deal with these conditions."
See the full blog posting proposing Frederic DDF and Clarisonic at BeautyResearch.com.
Defeat Clogged Pores with DDF and Clarisonic:
www.beautyresearch.com/blogs/beauty-research/archive/2012/02/28/defeat-clogged-pores-with-ddf-and-clarisonic.aspx
Beauty Research covers a variety of topics on the subject of beauty and health. Check out these recent blog postings:
Frederic Fekkai and Jan Marini for Remarkable Results
"We all know the importance of using professional hair care products... But for treating brittle, damaged and broken hair even the most professional products can fall short. When treating and effectively repairing severe hair breakage, the lines and product selection within those professional brands must be indication-specific for achieving the ultimate in results. That's why we here at Beauty Research highly recommend the superior brands Frederic Fekkai and Jan Marini."
Beauty Pros Agree - bareMinerals and Dermablend are Superior
"Painting on a pretty face has been around for thousands of years which is why cosmetic brands, services and businesses are a multi-billion dollar industry. Make-up, cosmetics, skin care and other beauty brands are always thinking of new and exciting ways to improve on their products. However, as with many beauty product companies the very best comes from professional lines. That is, brands and lines that are recommended or used by professional beauty and skincare practitioners. The line of thinking being... if a dermatologist recommends it... it's fairly certain and virtually guaranteed to work."
Beauty Research is a beauty blogging web site started by two experienced skin care enthusiasts wishing to share tips and suggestions. The DDF and Clarisonic article as well as a DDF and Clarisonic Forum can be found at BeautyResearch.com.
# # #
For the original version on PRWeb visit: www.prweb.com/releases/prweb2012/2/prweb9235407.htm
Article source: http://www.sfgate.com/cgi-bin/article.cgi?f=/g/a/2012/02/29/prweb9235407.DTL
NovaBay Issues Statement Regarding Market Activity
EMERYVILLE, Calif., Feb. 29, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide® compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, today issued the following statement:
In view of the unusual market activity in the company's stock on February 28, 2012, NYSE Amex contacted NovaBay in accordance with its usual practice, requiring that a press release be issued. NovaBay has not commented on unusual market activity historically, and in accordance with the company's public disclosure policy, has declined to comment on yesterday's trading.
The Company also reiterated that it plans to continue its track record of updating its shareholders with material news as appropriate in a timely manner.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary and patented Aganocide compounds. These are novel, synthetic anti-infectives with activity against bacteria, fungi and viruses, and are being developed to treat and prevent a wide range of local, non-systemic infections with a low likelihood of developing bacterial resistance.
NovaBay is focusing its technology on four distinct therapeutic areas: dermatology, ophthalmology, urology and hospital infections. In dermatology, the focus is on developing NVC-422 Gel formulation for the highly contagious skin infection, impetigo. NovaBay has the advantage of being partnered with Galderma, the leading dermatology company in the world. In ophthalmology, the goal is to develop an eye drop for viral conjunctivitis. In urology, NovaBay aims to reduce the incidence of urinary catheter blockage and encrustation (UCBE) and the associated urinary tract infections with an irrigation solution containing NVC-422. In hospital infections, NovaBay is targeting the six-million-patient market of chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers with its proprietary anti-infective solution, NeutroPhase®, the only pure hypochlorous acid solution, which has received two 510(k) clearances from the Food and Drug Administration. For additional information, visit: www.novabaypharma.com.
CONTACT: Investors:
NovaBay Pharmaceuticals, Inc.
Thomas J. Paulson
Chief Financial Officer
510-899-8809
tjpaulson@NovaBaypharma.com
Investors and Media:
The Ruth Group
Joshua Drumm, PhD (Investors)
(646) 536-7006
jdrumm@theruthgroup.com
Victoria Aguiar (Media)
(646) 536-7013
vaguiar@theruthgroup.com
Article source: http://www.globenewswire.com/newsroom/news.html?d=247550